spd-304 profile

SPD-304: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	5327044
CHEMBL ID	255489
SCHEMBL ID	1270919
MeSH ID	M0520049

Synonym
6,7-dimethyl-3-[(methyl{2-[methyl({1-[3-(trifluoromethyl)phenyl]-1h-indol-3-yl}methyl)amino]ethyl}amino)methyl]-4h-chromen-4-one
CHEMBL255489 ,
spd-304
6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one
bdbm50373071
spd304
cay10500
SCHEMBL1270919
DTXSID40416121
869998-49-2
NCGC00386701-02
jznxlppjrffecj-uhfffaoysa-n
6,7-dimethyl-3-((methyl-(2-(methyl-(1-(3-trifluoromethyl-phenyl)-1h-indol-3-ylmethyl)-amino)-ethyl)-amino)-methyl)-chromen-4-one
6,7-dimethyl-3-[[methyl[2-[methyl[[1-[3-(trifluoromethyl)phenyl]-1h-indol-3-yl]methyl]amino]ethyl]amino]methyl]-4h-1-benzopyran-4-one
HY-111255
CS-0034770
Q27453438
A936875
6,7-dimethyl-3-((methyl(2-(methyl((1-(3-(trifluoromethyl)phenyl)-1h-indol-3-yl)methyl)amino)ethyl)amino)methyl)-4h-chromen-4-one
EX-A6834
AKOS040738946

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Protein Targets (12)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	3.0112	0.0123	7.9835	43.2770	AID1645841
G	Vesicular stomatitis virus	Potency	21.3174	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	4.7724	0.0010	8.3798	61.1304	AID1645840
Interferon beta	Homo sapiens (human)	Potency	21.3174	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	21.3174	0.0123	8.9648	39.8107	AID1645842
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	21.3174	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	21.3174	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)	IC50 (µMol)	1.0000	1.0000	1.0000	1.0000	AID1676890
Tumor necrosis factor	Homo sapiens (human)	IC50 (µMol)	11.6250	0.2000	0.6791	1.3000	AID1372327; AID1443633; AID1443636; AID1758905
Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)	IC50 (µMol)	22.0000	7.0000	7.0000	7.0000	AID1198187
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Tumor necrosis factor	Homo sapiens (human)	Kd	13.3017	0.0027	4.2926	9.7700	AID1156798; AID1669371; AID318571; AID732923; AID732924; AID733374; AID733375; AID733376; AID733379; AID733380; AID733381; AID733382; AID733383; AID733384
Cytochrome P450 3A4	Homo sapiens (human)	Kd	91.7000	0.0130	0.4565	0.9000	AID1669371
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (273)

Process	via Protein(s)	Taxonomy
negative regulation of transcription by RNA polymerase II	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
ossification	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
osteoclast proliferation	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
monocyte chemotaxis	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
immune response	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
JNK cascade	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
positive regulation of gene expression	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
cytokine-mediated signaling pathway	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
calcium-mediated signaling	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
osteoclast differentiation	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
mammary gland epithelial cell proliferation	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
positive regulation of homotypic cell-cell adhesion	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
osteoclast development	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
paracrine signaling	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
positive regulation of MAP kinase activity	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
tooth eruption	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
bone resorption	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
positive regulation of osteoclast differentiation	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
positive regulation of bone resorption	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
positive regulation of JNK cascade	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
positive regulation of T cell activation	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
positive regulation of corticotropin-releasing hormone secretion	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
calcium ion homeostasis	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
mammary gland alveolus development	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
ERK1 and ERK2 cascade	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
positive regulation of fever generation by positive regulation of prostaglandin secretion	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
positive regulation of intracellular signal transduction	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
cellular response to leukemia inhibitory factor	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
positive regulation of osteoclast development	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
positive regulation of gene expression	Tumor necrosis factor	Homo sapiens (human)
negative regulation of gene expression	Tumor necrosis factor	Homo sapiens (human)
positive regulation of MAP kinase activity	Tumor necrosis factor	Homo sapiens (human)
positive regulation of MAPK cascade	Tumor necrosis factor	Homo sapiens (human)
positive regulation of interleukin-33 production	Tumor necrosis factor	Homo sapiens (human)
positive regulation of cytokine production involved in inflammatory response	Tumor necrosis factor	Homo sapiens (human)
negative regulation of miRNA transcription	Tumor necrosis factor	Homo sapiens (human)
positive regulation of miRNA transcription	Tumor necrosis factor	Homo sapiens (human)
negative regulation of signaling receptor activity	Tumor necrosis factor	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Tumor necrosis factor	Homo sapiens (human)
positive regulation of gene expression	Tumor necrosis factor	Homo sapiens (human)
negative regulation of gene expression	Tumor necrosis factor	Homo sapiens (human)
positive regulation of interleukin-8 production	Tumor necrosis factor	Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	Tumor necrosis factor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Tumor necrosis factor	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Tumor necrosis factor	Homo sapiens (human)
positive regulation of calcineurin-NFAT signaling cascade	Tumor necrosis factor	Homo sapiens (human)
positive regulation of cytokine production involved in inflammatory response	Tumor necrosis factor	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Tumor necrosis factor	Homo sapiens (human)
positive regulation of synoviocyte proliferation	Tumor necrosis factor	Homo sapiens (human)
positive regulation of I-kappaB phosphorylation	Tumor necrosis factor	Homo sapiens (human)
negative regulation of apoptotic signaling pathway	Tumor necrosis factor	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Tumor necrosis factor	Homo sapiens (human)
response to hypoxia	Tumor necrosis factor	Homo sapiens (human)
microglial cell activation	Tumor necrosis factor	Homo sapiens (human)
positive regulation of cytokine production	Tumor necrosis factor	Homo sapiens (human)
positive regulation of protein phosphorylation	Tumor necrosis factor	Homo sapiens (human)
negative regulation of endothelial cell proliferation	Tumor necrosis factor	Homo sapiens (human)
negative regulation of L-glutamate import across plasma membrane	Tumor necrosis factor	Homo sapiens (human)
macrophage activation involved in immune response	Tumor necrosis factor	Homo sapiens (human)
chronic inflammatory response to antigenic stimulus	Tumor necrosis factor	Homo sapiens (human)
leukocyte migration involved in inflammatory response	Tumor necrosis factor	Homo sapiens (human)
regulation of immunoglobulin production	Tumor necrosis factor	Homo sapiens (human)
negative regulation of cytokine production involved in immune response	Tumor necrosis factor	Homo sapiens (human)
positive regulation of chronic inflammatory response to antigenic stimulus	Tumor necrosis factor	Homo sapiens (human)
positive regulation of humoral immune response mediated by circulating immunoglobulin	Tumor necrosis factor	Homo sapiens (human)
skeletal muscle contraction	Tumor necrosis factor	Homo sapiens (human)
negative regulation of systemic arterial blood pressure	Tumor necrosis factor	Homo sapiens (human)
glucose metabolic process	Tumor necrosis factor	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Tumor necrosis factor	Homo sapiens (human)
inflammatory response	Tumor necrosis factor	Homo sapiens (human)
humoral immune response	Tumor necrosis factor	Homo sapiens (human)
JNK cascade	Tumor necrosis factor	Homo sapiens (human)
circadian rhythm	Tumor necrosis factor	Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptors	Tumor necrosis factor	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage	Tumor necrosis factor	Homo sapiens (human)
response to xenobiotic stimulus	Tumor necrosis factor	Homo sapiens (human)
response to virus	Tumor necrosis factor	Homo sapiens (human)
response to salt stress	Tumor necrosis factor	Homo sapiens (human)
response to fructose	Tumor necrosis factor	Homo sapiens (human)
negative regulation of heart rate	Tumor necrosis factor	Homo sapiens (human)
vascular endothelial growth factor production	Tumor necrosis factor	Homo sapiens (human)
positive regulation of gene expression	Tumor necrosis factor	Homo sapiens (human)
negative regulation of gene expression	Tumor necrosis factor	Homo sapiens (human)
negative regulation of lipid storage	Tumor necrosis factor	Homo sapiens (human)
response to activity	Tumor necrosis factor	Homo sapiens (human)
regulation of metabolic process	Tumor necrosis factor	Homo sapiens (human)
calcium-mediated signaling	Tumor necrosis factor	Homo sapiens (human)
extracellular matrix organization	Tumor necrosis factor	Homo sapiens (human)
osteoclast differentiation	Tumor necrosis factor	Homo sapiens (human)
sequestering of triglyceride	Tumor necrosis factor	Homo sapiens (human)
cortical actin cytoskeleton organization	Tumor necrosis factor	Homo sapiens (human)
positive regulation of protein-containing complex assembly	Tumor necrosis factor	Homo sapiens (human)
positive regulation of fever generation	Tumor necrosis factor	Homo sapiens (human)
negative regulation of myelination	Tumor necrosis factor	Homo sapiens (human)
response to nutrient levels	Tumor necrosis factor	Homo sapiens (human)
negative regulation of interleukin-6 production	Tumor necrosis factor	Homo sapiens (human)
positive regulation of chemokine production	Tumor necrosis factor	Homo sapiens (human)
positive regulation of fractalkine production	Tumor necrosis factor	Homo sapiens (human)
positive regulation of type II interferon production	Tumor necrosis factor	Homo sapiens (human)
positive regulation of interleukin-1 beta production	Tumor necrosis factor	Homo sapiens (human)
positive regulation of interleukin-18 production	Tumor necrosis factor	Homo sapiens (human)
positive regulation of interleukin-6 production	Tumor necrosis factor	Homo sapiens (human)
positive regulation of interleukin-8 production	Tumor necrosis factor	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Tumor necrosis factor	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Tumor necrosis factor	Homo sapiens (human)
positive regulation of heterotypic cell-cell adhesion	Tumor necrosis factor	Homo sapiens (human)
toll-like receptor 3 signaling pathway	Tumor necrosis factor	Homo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activity	Tumor necrosis factor	Homo sapiens (human)
response to isolation stress	Tumor necrosis factor	Homo sapiens (human)
response to macrophage colony-stimulating factor	Tumor necrosis factor	Homo sapiens (human)
vasodilation	Tumor necrosis factor	Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT protein	Tumor necrosis factor	Homo sapiens (human)
positive regulation of apoptotic process	Tumor necrosis factor	Homo sapiens (human)
positive regulation of programmed cell death	Tumor necrosis factor	Homo sapiens (human)
regulation of canonical NF-kappaB signal transduction	Tumor necrosis factor	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Tumor necrosis factor	Homo sapiens (human)
negative regulation of protein-containing complex disassembly	Tumor necrosis factor	Homo sapiens (human)
positive regulation of protein-containing complex disassembly	Tumor necrosis factor	Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic process	Tumor necrosis factor	Homo sapiens (human)
positive regulation of MAP kinase activity	Tumor necrosis factor	Homo sapiens (human)
positive regulation of MAPK cascade	Tumor necrosis factor	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Tumor necrosis factor	Homo sapiens (human)
positive regulation of JUN kinase activity	Tumor necrosis factor	Homo sapiens (human)
positive regulation of neuron apoptotic process	Tumor necrosis factor	Homo sapiens (human)
negative regulation of blood vessel endothelial cell migration	Tumor necrosis factor	Homo sapiens (human)
negative regulation of viral genome replication	Tumor necrosis factor	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	Tumor necrosis factor	Homo sapiens (human)
response to ethanol	Tumor necrosis factor	Homo sapiens (human)
regulation of fat cell differentiation	Tumor necrosis factor	Homo sapiens (human)
negative regulation of fat cell differentiation	Tumor necrosis factor	Homo sapiens (human)
negative regulation of myoblast differentiation	Tumor necrosis factor	Homo sapiens (human)
negative regulation of osteoblast differentiation	Tumor necrosis factor	Homo sapiens (human)
positive regulation of osteoclast differentiation	Tumor necrosis factor	Homo sapiens (human)
positive regulation of protein catabolic process	Tumor necrosis factor	Homo sapiens (human)
positive regulation of action potential	Tumor necrosis factor	Homo sapiens (human)
positive regulation of cell adhesion	Tumor necrosis factor	Homo sapiens (human)
positive regulation of mitotic nuclear division	Tumor necrosis factor	Homo sapiens (human)
negative regulation of DNA-templated transcription	Tumor necrosis factor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Tumor necrosis factor	Homo sapiens (human)
negative regulation of mitotic cell cycle	Tumor necrosis factor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Tumor necrosis factor	Homo sapiens (human)
positive regulation of translational initiation by iron	Tumor necrosis factor	Homo sapiens (human)
negative regulation of glucose import	Tumor necrosis factor	Homo sapiens (human)
positive regulation of JNK cascade	Tumor necrosis factor	Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STAT	Tumor necrosis factor	Homo sapiens (human)
astrocyte activation	Tumor necrosis factor	Homo sapiens (human)
embryonic digestive tract development	Tumor necrosis factor	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Tumor necrosis factor	Homo sapiens (human)
positive regulation of inflammatory response	Tumor necrosis factor	Homo sapiens (human)
negative regulation of neurogenesis	Tumor necrosis factor	Homo sapiens (human)
regulation of insulin secretion	Tumor necrosis factor	Homo sapiens (human)
positive regulation of synaptic transmission	Tumor necrosis factor	Homo sapiens (human)
regulation of synapse organization	Tumor necrosis factor	Homo sapiens (human)
defense response to Gram-positive bacterium	Tumor necrosis factor	Homo sapiens (human)
cognition	Tumor necrosis factor	Homo sapiens (human)
leukocyte tethering or rolling	Tumor necrosis factor	Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain	Tumor necrosis factor	Homo sapiens (human)
negative regulation of lipid catabolic process	Tumor necrosis factor	Homo sapiens (human)
positive regulation of membrane protein ectodomain proteolysis	Tumor necrosis factor	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	Tumor necrosis factor	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Tumor necrosis factor	Homo sapiens (human)
positive regulation of protein transport	Tumor necrosis factor	Homo sapiens (human)
response to glucocorticoid	Tumor necrosis factor	Homo sapiens (human)
positive regulation of hair follicle development	Tumor necrosis factor	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Tumor necrosis factor	Homo sapiens (human)
regulation of synaptic transmission, glutamatergic	Tumor necrosis factor	Homo sapiens (human)
positive regulation of glial cell proliferation	Tumor necrosis factor	Homo sapiens (human)
positive regulation of vitamin D biosynthetic process	Tumor necrosis factor	Homo sapiens (human)
positive regulation of calcidiol 1-monooxygenase activity	Tumor necrosis factor	Homo sapiens (human)
epithelial cell proliferation involved in salivary gland morphogenesis	Tumor necrosis factor	Homo sapiens (human)
regulation of branching involved in salivary gland morphogenesis	Tumor necrosis factor	Homo sapiens (human)
negative regulation of vascular wound healing	Tumor necrosis factor	Homo sapiens (human)
negative regulation of branching involved in lung morphogenesis	Tumor necrosis factor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Tumor necrosis factor	Homo sapiens (human)
cellular response to lipopolysaccharide	Tumor necrosis factor	Homo sapiens (human)
cellular response to amino acid stimulus	Tumor necrosis factor	Homo sapiens (human)
cellular response to retinoic acid	Tumor necrosis factor	Homo sapiens (human)
cellular response to nicotine	Tumor necrosis factor	Homo sapiens (human)
cellular response to type II interferon	Tumor necrosis factor	Homo sapiens (human)
cellular response to ionizing radiation	Tumor necrosis factor	Homo sapiens (human)
positive regulation of mononuclear cell migration	Tumor necrosis factor	Homo sapiens (human)
positive regulation of podosome assembly	Tumor necrosis factor	Homo sapiens (human)
endothelial cell apoptotic process	Tumor necrosis factor	Homo sapiens (human)
protein localization to plasma membrane	Tumor necrosis factor	Homo sapiens (human)
negative regulation of oxidative phosphorylation	Tumor necrosis factor	Homo sapiens (human)
inflammatory response to wounding	Tumor necrosis factor	Homo sapiens (human)
extrinsic apoptotic signaling pathway	Tumor necrosis factor	Homo sapiens (human)
cellular response to toxic substance	Tumor necrosis factor	Homo sapiens (human)
liver regeneration	Tumor necrosis factor	Homo sapiens (human)
necroptotic signaling pathway	Tumor necrosis factor	Homo sapiens (human)
negative regulation of bile acid secretion	Tumor necrosis factor	Homo sapiens (human)
antiviral innate immune response	Tumor necrosis factor	Homo sapiens (human)
response to Gram-negative bacterium	Tumor necrosis factor	Homo sapiens (human)
positive regulation of neuroinflammatory response	Tumor necrosis factor	Homo sapiens (human)
negative regulation of amyloid-beta clearance	Tumor necrosis factor	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Tumor necrosis factor	Homo sapiens (human)
positive regulation of amyloid-beta formation	Tumor necrosis factor	Homo sapiens (human)
response to L-glutamate	Tumor necrosis factor	Homo sapiens (human)
positive regulation of neutrophil activation	Tumor necrosis factor	Homo sapiens (human)
positive regulation of protein localization to plasma membrane	Tumor necrosis factor	Homo sapiens (human)
regulation of establishment of endothelial barrier	Tumor necrosis factor	Homo sapiens (human)
negative regulation of bicellular tight junction assembly	Tumor necrosis factor	Homo sapiens (human)
cellular response to amyloid-beta	Tumor necrosis factor	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	Tumor necrosis factor	Homo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cell	Tumor necrosis factor	Homo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cell	Tumor necrosis factor	Homo sapiens (human)
regulation of membrane lipid metabolic process	Tumor necrosis factor	Homo sapiens (human)
response to 3,3',5-triiodo-L-thyronine	Tumor necrosis factor	Homo sapiens (human)
response to gold nanoparticle	Tumor necrosis factor	Homo sapiens (human)
positive regulation of protein localization to cell surface	Tumor necrosis factor	Homo sapiens (human)
positive regulation of blood microparticle formation	Tumor necrosis factor	Homo sapiens (human)
positive regulation of chemokine (C-X-C motif) ligand 2 production	Tumor necrosis factor	Homo sapiens (human)
positive regulation of hepatocyte proliferation	Tumor necrosis factor	Homo sapiens (human)
regulation of endothelial cell apoptotic process	Tumor necrosis factor	Homo sapiens (human)
regulation of reactive oxygen species metabolic process	Tumor necrosis factor	Homo sapiens (human)
positive regulation of DNA biosynthetic process	Tumor necrosis factor	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligand	Tumor necrosis factor	Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway	Tumor necrosis factor	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
aortic valve development	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
pulmonary valve development	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
negative regulation of extracellular matrix constituent secretion	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
transcription by RNA polymerase II	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
prostaglandin metabolic process	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
inflammatory response	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptors	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
negative regulation of cardiac muscle hypertrophy	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathway	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
cytokine-mediated signaling pathway	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
positive regulation of amide metabolic process	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT protein	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
defense response to bacterium	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
positive regulation of lipid metabolic process	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
negative regulation of inflammatory response	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
positive regulation of inflammatory response	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
cellular response to mechanical stimulus	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
protein localization to plasma membrane	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
positive regulation of apoptotic process involved in morphogenesis	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
regulation of establishment of endothelial barrier	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
regulation of membrane lipid metabolic process	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
long-chain fatty acid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C19	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (54)

Process	via Protein(s)	Taxonomy
cytokine activity	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
tumor necrosis factor receptor binding	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
protein binding	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
tumor necrosis factor receptor superfamily binding	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
identical protein binding	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
transcription cis-regulatory region binding	Tumor necrosis factor	Homo sapiens (human)
protease binding	Tumor necrosis factor	Homo sapiens (human)
cytokine activity	Tumor necrosis factor	Homo sapiens (human)
tumor necrosis factor receptor binding	Tumor necrosis factor	Homo sapiens (human)
protein binding	Tumor necrosis factor	Homo sapiens (human)
death receptor agonist activity	Tumor necrosis factor	Homo sapiens (human)
identical protein binding	Tumor necrosis factor	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
tumor necrosis factor receptor activity	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
protein binding	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
tumor necrosis factor binding	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C19	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxygen binding	Cytochrome P450 2C19	Homo sapiens (human)
enzyme binding	Cytochrome P450 2C19	Homo sapiens (human)
heme binding	Cytochrome P450 2C19	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C19	Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C19	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (30)

Process	via Protein(s)	Taxonomy
extracellular region	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
extracellular space	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
cytoplasm	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
plasma membrane	Tumor necrosis factor ligand superfamily member 11	Homo sapiens (human)
extracellular space	Tumor necrosis factor	Homo sapiens (human)
phagocytic cup	Tumor necrosis factor	Homo sapiens (human)
extracellular region	Tumor necrosis factor	Homo sapiens (human)
extracellular space	Tumor necrosis factor	Homo sapiens (human)
plasma membrane	Tumor necrosis factor	Homo sapiens (human)
external side of plasma membrane	Tumor necrosis factor	Homo sapiens (human)
cell surface	Tumor necrosis factor	Homo sapiens (human)
neuronal cell body	Tumor necrosis factor	Homo sapiens (human)
membrane raft	Tumor necrosis factor	Homo sapiens (human)
recycling endosome	Tumor necrosis factor	Homo sapiens (human)
cell surface	Tumor necrosis factor	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
Golgi membrane	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
extracellular region	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
extracellular space	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
plasma membrane	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
cell surface	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
membrane	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
membrane raft	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
tumor necrosis factor receptor superfamily complex	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
receptor complex	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
membrane raft	Tumor necrosis factor receptor superfamily member 1A	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C19	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (55)

Assay ID	Title	Year	Journal	Article
AID733398	Solubility of the compound in 5 % glycerol by UV/visible spectroscopy	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID733385	Solubility of the compound in citrate-phosphate buffer at pH 6.5	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID733393	Solubility of the compound in 2.5 % PEG3350 by UV/visible spectroscopy	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID733380	Binding affinity to GST-tagged human TNF-alpha by fluorescence assay in presence of 2.5 % DMF as solvent	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID733391	Solubility of the compound in 5 % MeOH by UV/visible spectroscopy	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID733390	Solubility of the compound in 10 % PEG3350 by UV/visible spectroscopy	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID1198187	Inhibition of TNFR1 (unknown origin)	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Synthesis and biological evaluation of pyridazino[1',6':1,2]pyrido[3,4-b]indolinium and pyridazino[1,6-a]benzimidazolium salts as anti-inflammatory agents.
AID733400	Solubility of the compound in 5 % DMF by UV/visible spectroscopy	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID1870948	Anti-osteoporosis activity C57/BL6 mouse bone marrow macrophage cells assessed as inhibition of RANKL-induced osteoclastogenesis at 1 uM measured after 5 to 6 days in presence of M-CSF and RNKL by TRAP staining microscopic analysis	2022	Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16	Development of an Orally Active Small-Molecule Inhibitor of Receptor Activator of Nuclear Factor-κB Ligand.
AID733386	Solubility of the compound in 2.5 % PEG5000 by UV/visible spectroscopy	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID1676891	Binding affinity to GST-fused human RANKL extracellular domain (Lys159 to Asp317 residues) expressed in Escherichia coli BL21(DE3) pLysS by fluorescence spectrophotometric assay	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Discovery of Small-Molecule Inhibitors of Receptor Activator of Nuclear Factor-κB Ligand with a Superior Therapeutic Index.
AID733397	Solubility of the compound in 2.5 % glycerol by UV/visible spectroscopy	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID1870950	Cytotoxicity against C57/BL6 mouse bone marrow macrophage cells assessed as reduction in cell viability at 10 uM incubated for 3 days by CCK8 assay	2022	Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16	Development of an Orally Active Small-Molecule Inhibitor of Receptor Activator of Nuclear Factor-κB Ligand.
AID733381	Binding affinity to GST-tagged human TNF-alpha by fluorescence assay in presence of 2.5 % PEG3350 as solvent	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID1676887	Therapeutic index, ratio of LC50 for mouse bone marrow cells to IC50 for Inhibition of human RANKL-induced osteoclastogenesis in RANKL cultured mouse bone marrow cells	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Discovery of Small-Molecule Inhibitors of Receptor Activator of Nuclear Factor-κB Ligand with a Superior Therapeutic Index.
AID733374	Binding affinity to GST-tagged human TNF-alpha by fluorescence assay in presence of 5 % PEG3350 as solvent	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID1676890	Inhibition of human RANKL-induced osteoclastogenesis in RANKL cultured mouse bone marrow cells assessed as reduction in RANKL/M-CSF-induced TRAP activity preincubated with RANKL for 1 hr followed by cell addition and subsequent media replenishment every 4	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Discovery of Small-Molecule Inhibitors of Receptor Activator of Nuclear Factor-κB Ligand with a Superior Therapeutic Index.
AID733395	Solubility of the compound in 2.5 % MeOH by UV/visible spectroscopy	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID733392	Solubility of the compound in 10 % MeOH by UV/visible spectroscopy	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID318571	Binding affinity to TNF	2007	Nature, Dec-13, Volume: 450, Issue:7172	Reaching for high-hanging fruit in drug discovery at protein-protein interfaces.
AID1758905	Inhibition of TNFR1 binding to human TNFalpha expressed in Escherichia coli BL21 (DE3) incubated for 60 mins by ELISA	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Rationally designed TNF-α inhibitors: Identification of promising cytotoxic agents.
AID1870949	Anti-osteoporosis activity C57/BL6 mouse bone marrow macrophage cells assessed as inhibition of RANKL-induced osteoclastogenesis at 0.1 uM measured after 5 to 6 days in presence of M-CSF and RNKL by TRAP staining microscopic analysis	2022	Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16	Development of an Orally Active Small-Molecule Inhibitor of Receptor Activator of Nuclear Factor-κB Ligand.
AID1372327	Inhibition of TNF-alpha (unknown origin) binding to TNFR1 by ELISA	2018	Bioorganic & medicinal chemistry letters, 01-01, Volume: 28, Issue:1	Synthesis and in vitro evaluations of 6-(hetero)-aryl-imidazo[1,2-b]pyridazine-3-sulfonamide's as an inhibitor of TNF-α production.
AID1676888	Inhibition of human soluble RANKL trimerization assessed as increase in RANKL monomer level at 1:3 to 1:10 ratio of DSS to RANKL preincubated for 1 hr followed by DSS addition and measured after 1 hr by SDS-PAGE analysis	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Discovery of Small-Molecule Inhibitors of Receptor Activator of Nuclear Factor-κB Ligand with a Superior Therapeutic Index.
AID732924	Binding affinity to GST-tagged human TNF-alpha by fluorescence assay in presence of 5 % MeOH as solvent	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID1443636	Binding affinity to human TNF-alpha soluble domain assessed as decrease in complex formation with human TNFR2 extracellular domain preincubated for 1 hr followed by receptor addition measure after 2 hrs by TR-FRET assay	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Structural Basis of Small-Molecule Aggregate Induced Inhibition of a Protein-Protein Interaction.
AID1676889	Cytotoxicity against mouse BMMC assessed as reduction in cell viability measured after 48 hrs by MTT assay	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Discovery of Small-Molecule Inhibitors of Receptor Activator of Nuclear Factor-κB Ligand with a Superior Therapeutic Index.
AID733379	Binding affinity to GST-tagged human TNF-alpha by fluorescence assay in presence of 10 % PEG3350 as solvent	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID733401	Solubility of the compound in 5 % DMSO by UV/visible spectroscopy	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID1443633	Binding affinity to human TNF-alpha soluble domain assessed as decrease in complex formation with human TNFR1 extracellular domain preincubated for 1 hr followed by receptor addition measure after 2 hrs by TR-FRET assay	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Structural Basis of Small-Molecule Aggregate Induced Inhibition of a Protein-Protein Interaction.
AID733399	Solubility of the compound in 2.5 % DMF by UV/visible spectroscopy	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID733402	Solubility of the compound in 10 % DMSO by UV/visible spectroscopy	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID733376	Binding affinity to GST-tagged human TNF-alpha by fluorescence assay in presence of 5 % DMSO as solvent	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID733377	Binding affinity to GST-tagged human TNF-alpha in 10 mM citrate-phosphate at pH 6.5 assessed as reduction in fluorescence signal measuring quenching by fluorescence assay	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID1669371	Binding affinity to recombinant TNFalpha (unknown origin) expressed in Escherichia coli BL21 (DE3) incubated for 10 mins by MST assay	2020	Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15	Discovery of an Orally Active Small-Molecule Tumor Necrosis Factor-α Inhibitor.
AID733389	Solubility of the compound in 5 % PEG3350 by UV/visible spectroscopy	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID733375	Binding affinity to GST-tagged human TNF-alpha by fluorescence assay in presence of 2.5 % MeOH as solvent	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID733388	Solubility of the compound in 10 % PEG5000 by UV/visible spectroscopy	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID733384	Binding affinity to GST-tagged human TNF-alpha in 10 mM citrate-phosphate at pH 6.5 by fluorescence assay	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID733382	Binding affinity to GST-tagged human TNF-alpha by fluorescence assay in presence of 10 % DMSO as solvent	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID1676884	Cytotoxicity against mouse BMMC assessed as reduction in cell viability at 5 uM measured after 48 hrs by MTT assay	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Discovery of Small-Molecule Inhibitors of Receptor Activator of Nuclear Factor-κB Ligand with a Superior Therapeutic Index.
AID732923	Binding affinity to GST-tagged human TNF-alpha by fluorescence assay in presence of 10 % MeOH as solvent	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID733387	Solubility of the compound in 5 % PEG5000 by UV/visible spectroscopy	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID1443635	Critical aggregation concentration assessed as formation of aggregate after 30 mins by light scattering method	2017	Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8	Structural Basis of Small-Molecule Aggregate Induced Inhibition of a Protein-Protein Interaction.
AID733396	Solubility of the compound in 10 % DMF by UV/visible spectroscopy	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID733403	Solubility of the compound in 2.5 % DMSO by UV/visible spectroscopy	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID733394	Solubility of the compound in 10 % glycerol by UV/visible spectroscopy	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID1156798	Binding affinity to TNF-alpha (unknown origin)	2014	European journal of medicinal chemistry, Aug-18, Volume: 83	Prediction of anti-tumor chemical probes of a traditional Chinese medicine formula by HPLC fingerprinting combined with molecular docking.
AID733378	Ratio of Kd for GST-tagged human TNF-alpha in presence of methanol as solvent to Kd for GST-tagged human TNF-alpha in presence of DMSO	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID733383	Binding affinity to GST-tagged human TNF-alpha by fluorescence assay in presence of 2.5 % DMSO as solvent	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (11.11)	29.6817
2010's	10 (55.56)	24.3611
2020's	6 (33.33)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (5.56%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	17 (94.44%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
gallic acid gallate : A trihydroxybenzoate that is the conjugate base of gallic acid.	2.11	1	trihydroxybenzoic acid	antineoplastic agent; antioxidant; apoptosis inducer; astringent; cyclooxygenase 2 inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; geroprotector; human xenobiotic metabolite; plant metabolite
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	2.31	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
miconazole Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion.. 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group.. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.	2.15	1	dichlorobenzene; ether; imidazoles
pd 169316 2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole: p38 MAP kinase inhibitor	2.08	1	imidazoles
rolipram [no description available]	2.17	1	pyrrolidin-2-ones	antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.	2.25	1	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
skatole [no description available]	2.04	1	methylindole	human metabolite; mammalian metabolite
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.08	1	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
daidzin daidzin: a potent, selective, and reversible inhibitor of human mitochondrial aldehyde dehydrogenase. daidzein 7-O-beta-D-glucoside : A glycosyloxyisoflavone that is daidzein attached to a beta-D-glucopyranosyl residue at position 7 via a glycosidic linkage. It is used in the treatment of alcohol dependency (antidipsotropic).	2.1	1	7-hydroxyisoflavones 7-O-beta-D-glucoside; hydroxyisoflavone; monosaccharide derivative	plant metabolite
oleanolic acid 3-acetate oleanolic acid 3-acetate: from Gardenia jasminoides; RN given for (3beta)-isomer	2.1	1
angiotensin ii Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).	2.08	1	amino acid zwitterion; angiotensin II	human metabolite
nsc 23766 [no description available]	3.13	1	aminopyrimidine; aminoquinoline; primary amino compound; secondary amino compound; tertiary amino compound	antiviral agent; apoptosis inducer; EC 3.6.5.2 (small monomeric GTPase) inhibitor; muscarinic antagonist
ononin [no description available]	2.1	1	4'-methoxyisoflavones; 7-hydroxyisoflavones 7-O-beta-D-glucoside; monosaccharide derivative	plant metabolite
dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	2.08	1	actinomycin	mutagen
ganoderic acid a [no description available]	2.1	1	triterpenoid
ganoderiol f ganoderiol F: a ganoderma triterpene from Ganoderma amboinense; structure in first source	2.1	1	triterpenoid
isopropyl thiogalactoside Isopropyl Thiogalactoside: A non-metabolizable galactose analog that induces expression of the LAC OPERON.. isopropyl beta-D-thiogalactopyranoside : An S-glycosyl compound consisting of beta-D-1-thiogalactose having an isopropyl group attached to the anomeric sulfur.	2.08	1	S-glycosyl compound
nbd 556 [no description available]	3.13	1
formononetin [no description available]	2.1	1	4'-methoxyisoflavones; 7-hydroxyisoflavones	phytoestrogen; plant metabolite
luteolin [no description available]	2.1	1	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist
7,3'-dihydroxy-4'-methoxyisoflavone 7,3'-dihydroxy-4'-methoxyisoflavone: isolated from Astragali radix; structure in first source. calycosin : A member of the class of 7-hydroxyisoflavones that is 7-hydroxyisoflavone which is substituted by an additional hydroxy group at the 3' position and a methoxy group at the 4' position.	2.1	1	4'-methoxyisoflavones; 7-hydroxyisoflavones	antioxidant; metabolite
luteolin-7-glucoside luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum. luteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.	2.1	1	beta-D-glucoside; glycosyloxyflavone; monosaccharide derivative; trihydroxyflavone	antioxidant; plant metabolite
apigetrin apigetrin: structure given in first source. apigenin 7-O-beta-D-glucoside : A glycosyloxyflavone that is apigenin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.	2.1	1	beta-D-glucoside; dihydroxyflavone; glycosyloxyflavone; monosaccharide derivative	antibacterial agent; metabolite; non-steroidal anti-inflammatory drug
N(2)-carbamimidoyl-N-{2-[4-(3-{4-[(5-carboxyfuran-2-yl)methoxy]-2,3-dichlorophenyl}-1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-2-oxoethyl}-D-leucinamide N(2)-carbamimidoyl-N-{2-[4-(3-{4-[(5-carboxyfuran-2-yl)methoxy]-2,3-dichlorophenyl}-1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-2-oxoethyl}-D-leucinamide : A leucine derivative obtained by fpormal condensation of the secondary amino group of 5-({2,3-dichloro-4-[1-methyl-5-(piperidin-4-yl)-1H-pyrazol-3-yl]phenoxy}methyl)-2-furoic acid and the carboxy group of N-amidino-L-leucylglycine	3.13	1	D-leucine derivative; dichlorobenzene; furoic acid; glycine derivative; guanidines; pyrazolylpiperidine
pd 123319 PD123319 : An imidazopyridine consisting of 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine having 4-(dimethylamino)-3-methylbenzyl, diphenylacetyl and carboxy and groups at positions 1, 5 and 6 respectively	2.08	1	imidazopyridine	angiotensin receptor antagonist; endothelin receptor antagonist; vasoconstrictor agent
calycosin-7-o-beta-d-glucopyranoside calycosin-7-O-beta-D-glucoside: from Radix Astragali. calycosin-7-O-beta-D-glucoside : A glycosyloxyisoflavone that is calycosin substituted by a beta-D-glucopyranosyl residue at position at 7 via a glycosidic linkage.	2.1	1	4'-methoxyisoflavones; 7-hydroxyisoflavones 7-O-beta-D-glucoside; hydroxyisoflavone; monosaccharide derivative
abt-737 [no description available]	3.13	1	aromatic amine; aryl sulfide; biphenyls; C-nitro compound; monochlorobenzenes; N-arylpiperazine; N-sulfonylcarboxamide; secondary amino compound; tertiary amino compound	anti-allergic agent; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
nutlin-3a nutlin 3: an MDM2 antagonist; structure in first source	3.13	1	stilbenoid
diosgenin glucoside diosgenin glucoside: RN given refers to (3beta,25R)-isomer; structure given in first source. diosgenin 3-O-beta-D-glucoside : A sterol 3-beta-D-glucoside having diosgenin as the sterol component.	2.1	1	hexacyclic triterpenoid; monosaccharide derivative; spiroketal; sterol 3-beta-D-glucoside	metabolite
astragaloside IV [no description available]	2.1	1	pentacyclic triterpenoid; triterpenoid saponin	anti-inflammatory agent; antioxidant; EC 4.2.1.1 (carbonic anhydrase) inhibitor; neuroprotective agent; plant metabolite; pro-angiogenic agent
ganoderic acid f ganoderic acid F: isolated from Ganoderma lucidum; structure in first source	2.1	1	triterpenoid
ganoderic acid c2 ganoderic acid C2: from the fruiting body of Ganoderma; structure in first source	2.1	1	triterpenoid

Condition	Relationship Strength	Studies
Congenital Zika Syndrome [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.25	1
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1
Bone Loss, Osteoclastic [description not available]	2.41	1
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	2.11	1

spd-304

Description

Cross-References

Synonyms (21)

Research Excerpts

Bioavailability

Protein Targets (12)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (273)

Molecular Functions (54)

Ceullar Components (30)

Bioassays (55)

Research

Studies (18)

Market Indicators

Research Demand Index: 21.81

Study Types

spd-304

Description

Cross-References

Synonyms (21)

Research Excerpts

Bioavailability

Protein Targets (12)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (273)

Molecular Functions (54)

Ceullar Components (30)

Bioassays (55)

Research

Studies (18)

Market Indicators

Research Demand Index: 21.81

Study Types

Related Drugs (32)

Related Conditions (5)